Trial Profile
An Open Phase I Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Cafusertib Hydrochloride in Combination With Subcutaneous Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Cafusertib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 31 May 2014 New trial record